Abiopharma

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

New Form 8-K - MIRA PHARMACEUTICALS, INC. Filed: 2025-06-30 AccNo: 0001641172-25-017046 Size: 213 KB Item 8.01: Other Events

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell3000® Index

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

Disclosure Of Interest/ Changes In Interest Of Substantial Shareholder(s)/ Unitholder(s) - Change In Interest - Lee Keck Keong

FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS

New Form 8-K - CASSAVA SCIENCES INC Filed: 2025-06-30 AccNo: 0001171843-25-004211 Size: 231 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Celcuity Inc. Filed: 2025-06-30 AccNo: 0001641172-25-017043 Size: 278 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Celcuity Inc Notification (CELC)

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

New Form 8-K - INDIVIOR PLC Filed: 2025-06-30 AccNo: 0001625297-25-000046 Size: 159 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits